Baumert, B., Deimling, A. v., Hartmann, C., Capper, D., & Wick, W. (2016). Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): A randomised, open-label, phase 3 intergroup study. The lancet. Oncology, 17(11), . https://doi.org/10.1016/S1470-2045(16)30313-8
Chicago-Zitierstil (17. Ausg.)Baumert, Brigitta, Andreas von Deimling, Christian Hartmann, David Capper, und Wolfgang Wick. "Temozolomide Chemotherapy Versus Radiotherapy in High-risk Low-grade Glioma (EORTC 22033-26033): A Randomised, Open-label, Phase 3 Intergroup Study." The Lancet. Oncology 17, no. 11 (2016). https://doi.org/10.1016/S1470-2045(16)30313-8.
MLA-Zitierstil (9. Ausg.)Baumert, Brigitta, et al. "Temozolomide Chemotherapy Versus Radiotherapy in High-risk Low-grade Glioma (EORTC 22033-26033): A Randomised, Open-label, Phase 3 Intergroup Study." The Lancet. Oncology, vol. 17, no. 11, 2016, https://doi.org/10.1016/S1470-2045(16)30313-8.